RT Journal Article
SR Electronic
T1 Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.25.21257828
DO 10.1101/2021.05.25.21257828
A1 Morinaga, Yoshitomo
A1 Tani, Hideki
A1 Terasaki, Yasushi
A1 Nomura, Satoshi
A1 Kawasuji, Hitoshi
A1 Shimada, Takahisa
A1 Igarashi, Emiko
A1 Saga, Yumiko
A1 Yoshida, Yoshihiro
A1 Yasukochi, Rei
A1 Kaneda, Makito
A1 Murai, Yushi
A1 Ueno, Akitoshi
A1 Miyajima, Yuki
A1 Fukui, Yasutaka
A1 Nagaoka, Kentaro
A1 Ono, Chikako
A1 Matsuura, Yoshiharu
A1 Fujimura, Takashi
A1 Ishida, Yoichi
A1 Oishi, Kazunori
A1 Yamamoto, Yoshihiro
YR 2021
UL http://medrxiv.org/content/early/2021/05/27/2021.05.25.21257828.abstract
AB Background Serological tests are beneficial for recognizing the immune response against SARS-CoV-2. To identify protective immunity, optimization of the chemiluminescent reduction neutralizing test (CRNT), using pseudotyped SARS-CoV-2, is critical. Whether commercial antibody tests are comparably accurate is unknown.Methods Serum samples collected before variants were locally found were obtained from confirmed COVID-19 patients (n = 74), confirmed non-COVID-19 individuals (n = 179), and unscreened individuals (suspected healthy individuals, n = 229). The convalescent phase was defined as the period after day 10 from disease onset. The CRNT against pseudotyped viruses displaying the wild-type spike protein and a commercially available anti-receptor binding domain (RBD) antibody test were assayed. The CRNT was also assayed, using South African (SA) and United Kingdom (UK)-derived variants.Results The CRNT (cut off value, 50% inhibition) and the anti-RBD antibody test (cut off value, 0.8 U/mL) concurred regarding symptomatic COVID-19 patients in the convalescent phase and clearly differentiated between patients and suspected healthy individuals (sensitivity; 95.8% and 100%, specificity; 99.1% and 100%, respectively). Anti-RBD antibody test results correlated with neutralizing titer (r = 0.47, 95% CI 0.20-0.68). Compared with the wild-type, CRNT reduction was observed for the SA and UK-derived variants. Of the samples with ≥100 U/mL by the anti-RBD antibody test, 77.8% and 88.9% showed ≥50% neutralization against the UK and the SA variants, respectively.Conclusion The CRNT and commercial anti-RBD antibody test effectively classified convalescent COVID-19 patients. The strong positive results using the commercial antibody test can reflect neutralizing activity against emerging variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Research Program on Emerging and Re-emerging Infectious Diseases from AMED Grant No. JP20he0622035.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed in accordance with the Declaration of Helsinki and was approved by the ethical review board of the University of Toyama (approval No.: R2019167 and R2020097).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data are in the figures and Tables including supplementary data.CRNTChemiluminescent reduction neutralizing testRBDReceptor binding domainRT-qPCRQuantitative reverse transcriptase–polymerase chain reactionVSVVesicular stomatitis virusDMEMDulbecco’s modified Eagle’s mediumFBSFetal bovine serumCOVCut-off value